Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Capital Expenditures (2023 - 2025)

Historic Capital Expenditures for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $651000.0.

  • Monte Rosa Therapeutics' Capital Expenditures rose 6315.79% to $651000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 2508.19%. This contributed to the annual value of $4.0 million for FY2024, which is 7905.57% down from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Capital Expenditures stood at $651000.0, which was up 6315.79% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Capital Expenditures peaked at $9.2 million during Q1 2023, and registered a low of $183000.0 during Q4 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $1.7 million (2023), whereas its average is $2.5 million.
  • In the last 5 years, Monte Rosa Therapeutics' Capital Expenditures plummeted by 8916.52% in 2024 and then skyrocketed by 6315.79% in 2025.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Capital Expenditures stood at $1.7 million in 2023, then plummeted by 89.17% to $183000.0 in 2024, then skyrocketed by 255.74% to $651000.0 in 2025.
  • Its last three reported values are $651000.0 in Q3 2025, $1.7 million for Q2 2025, and $1.6 million during Q1 2025.